Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NAVID EZRA

Allopathic & Osteopathic Physicians Dermatology

NPI
1104110071
CMS profile
230966
Location
THOUSAND OAKS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$160,808.97

169 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $76,275.67 56
ABBVIE INC. $60,783.63 69
Amgen Inc. $11,356.62 20
UCB, Inc. $6,367.74 5
E.R. Squibb & Sons, L.L.C. $5,482.97 5
Novartis Pharmaceuticals Corporation $164.55 2
GENZYME CORPORATION $126.04 4
Dermavant Sciences, Inc. $105.28 1
PFIZER INC. $44.36 2
Organogenesis Inc. $38.95 2
LEO Pharma Inc. $22.36 1
Sun Pharmaceutical Industries Inc. $21.76 1
Galderma Laboratories, L.P. $19.04 1

Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NAVID EZRA

NPI 1104110071 · CMS profile ID 230966

Allopathic & Osteopathic Physicians / Dermatology

THOUSAND OAKS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104110071?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NAVID EZRA, NPI 1104110071, CMS profile ID 230966. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104110071?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NAVID EZRA, NPI 1104110071, CMS profile ID 230966. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104110071?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NAVID EZRA, NPI 1104110071, CMS profile ID 230966, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1104110071?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

169 matching records · $160,808.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 169 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 169.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $24.7403/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020647783 CMS
ABBVIE INC. $1,725.0003/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223503 CMS
Lilly USA, LLC $21.8003/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031924393 CMS
Lilly USA, LLC $125.0003/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032068039 CMS
Lilly USA, LLC $8.3603/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032068043 CMS
ABBVIE INC. $6.3103/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223499 CMS
ABBVIE INC. $2,875.0003/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223501 CMS
ABBVIE INC. $8.0003/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223497 CMS
ABBVIE INC. $121.1203/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223495 CMS
ABBVIE INC. $2,875.0003/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223493 CMS
Lilly USA, LLC $1,800.0003/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032091439 CMS
Organogenesis Inc. $24.5403/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048111413 CMS
ABBVIE INC. $28.4503/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223491 CMS
Galderma Laboratories, L.P. $19.0403/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059693871 CMS
ABBVIE INC. $124.9903/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223489 CMS
Lilly USA, LLC $1,350.0002/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031924389 CMS
Lilly USA, LLC $3,600.0002/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032068021 CMS
Novartis Pharmaceuticals Corporation $102.0002/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991592553 CMS
GENZYME CORPORATION $24.5202/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050270743 CMS
PFIZER INC. $20.6502/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049627783 CMS
Lilly USA, LLC $3,150.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031924379 CMS
Lilly USA, LLC $3,600.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032091443 CMS
Lilly USA, LLC $2,250.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032091445 CMS
ABBVIE INC. $20.5602/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223485 CMS
ABBVIE INC. $27.2302/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223487 CMS
Lilly USA, LLC $3,600.0002/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031924383 CMS
Lilly USA, LLC $121.8202/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031965173 CMS
Lilly USA, LLC $16.0902/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032091449 CMS
Amgen Inc. $30.9602/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020647781 CMS
Amgen Inc. $27.2902/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020647779 CMS
ABBVIE INC. $2,875.0002/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223483 CMS
Lilly USA, LLC $6,750.0002/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031965159 CMS
Lilly USA, LLC $3,600.0002/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032040575 CMS
Lilly USA, LLC $2,250.0002/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032114613 CMS
GENZYME CORPORATION $26.5702/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050270733 CMS
ABBVIE INC. $125.0002/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997223481 CMS
Lilly USA, LLC $32.4602/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031965177 CMS
Lilly USA, LLC $17.7602/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032114621 CMS
Lilly USA, LLC $329.0002/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031955563 CMS
Lilly USA, LLC $271.8002/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031955569 CMS
Lilly USA, LLC $49.8902/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031965153 CMS
Lilly USA, LLC $252.6502/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032040557 CMS
Lilly USA, LLC $160.8002/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032067997 CMS
Lilly USA, LLC $139.6602/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032068003 CMS
Lilly USA, LLC $3,600.0002/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032068013 CMS
Lilly USA, LLC $2,250.0002/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032068017 CMS
Lilly USA, LLC $50.0002/01/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032091423 CMS
Lilly USA, LLC $44.8902/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032091427 CMS
Lilly USA, LLC $59.8502/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032091431 CMS
Lilly USA, LLC $160.8002/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032091435 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $124,297.76 179
PY2020 $52,480.36 94
PY2021 $48,014.77 105
PY2022 $209,346.66 288
PY2023 $160,808.97 169
PY2024 $119,208.64 119
PY2025 $91,524.89 70

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,176,536.15 478
PY2024 Recipient $9,541.92 12
PY2024 Principal investigator $2,209,399.58 227
PY2023 Recipient $24,485.31 12
PY2023 Principal investigator $601,126.30 163
PY2022 Principal investigator $454,041.07 141
PY2021 Principal investigator $632,449.47 86
PY2020 Principal investigator $400,504.22 83
PY2019 Recipient $3,000.00 1
PY2019 Principal investigator $472,308.11 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

478 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $665.04 12/31/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis No dispute reported 06/30/2026 1202533893
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202533895
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202533897
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $14,000.00 12/26/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235995273
Principal investigator 1 Incyte Corporation $1,555.20 12/19/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482147
Principal investigator 1 Incyte Corporation $1,663.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561119
Principal investigator 1 Incyte Corporation $1,670.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561146
Principal investigator 1 Incyte Corporation $1,670.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561152
Principal investigator 1 Incyte Corporation $52.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561221
Principal investigator 1 Incyte Corporation $52.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561227
Principal investigator 1 Incyte Corporation $52.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561233
Principal investigator 1 Incyte Corporation $52.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561239
Principal investigator 1 Incyte Corporation $52.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561244
Principal investigator 1 Incyte Corporation $52.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561249
Principal investigator 1 Incyte Corporation $52.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561254
Principal investigator 1 Incyte Corporation $52.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561261
Principal investigator 1 Incyte Corporation $52.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561268
Principal investigator 1 Incyte Corporation $1,922.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561272
Principal investigator 1 Incyte Corporation $1,922.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561278
Principal investigator 1 Incyte Corporation $2,244.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561354
Principal investigator 1 Incyte Corporation $1,968.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561431
Principal investigator 1 Incyte Corporation $1,968.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561435
Principal investigator 1 Incyte Corporation $2,047.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561441
Principal investigator 1 Incyte Corporation $2,071.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561449
Principal investigator 1 Incyte Corporation $2,168.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561455
Principal investigator 1 Incyte Corporation $3,642.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561472
Principal investigator 1 Incyte Corporation $2,335.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561476
Principal investigator 1 Incyte Corporation $2,335.00 12/19/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561481
Principal investigator 1 Incyte Corporation $198.00 12/18/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561395
Principal investigator 1 Incyte Corporation $99.00 12/18/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561466
Principal investigator 1 Incyte Corporation $11,050.00 12/17/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519548
Principal investigator 1 Incyte Corporation $2,077.00 12/17/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519552
Principal investigator 1 Incyte Corporation $99.00 12/17/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561315
Principal investigator 1 Incyte Corporation $83.00 12/17/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561385
Principal investigator 1 Incyte Corporation $635.00 12/17/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561538
Principal investigator 1 Incyte Corporation $138.00 12/17/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561565
Principal investigator 1 SANOFI PASTEUR INC. $200.00 12/17/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103316
Principal investigator 1 PFIZER INC. $18,056.28 12/16/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228804491
Principal investigator 1 ABBVIE INC. $43,042.02 12/11/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202530122
Principal investigator 1 Incyte Corporation $40.00 12/11/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482114
Principal investigator 1 Incyte Corporation $635.00 12/10/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561321
Principal investigator 1 Incyte Corporation $99.00 12/10/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561388
Principal investigator 1 Incyte Corporation $138.00 12/10/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561571
Principal investigator 1 SANOFI US SERVICES INC. $24,450.00 12/08/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226132912
Principal investigator 1 Incyte Corporation $2,755.10 12/05/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561513
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $220.00 12/05/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289302
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $110.00 12/05/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289304
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $110.00 12/05/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289306
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $310.50 12/05/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289310
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $62.10 12/05/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289312
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $62.10 12/05/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289324
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $110.00 12/05/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289326
Principal investigator 1 ABBVIE INC. $10,301.40 12/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527720
Principal investigator 1 ABBVIE INC. $8,964.60 12/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527722
Principal investigator 1 ABBVIE INC. $3,055.90 12/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202527724
Principal investigator 1 ABBVIE INC. $7,932.70 12/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202527924
Principal investigator 1 Incyte Corporation $168.00 12/04/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240482085
Principal investigator 1 Incyte Corporation $423.00 12/04/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240482090
Principal investigator 1 Incyte Corporation $10,000.00 12/04/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240482095
Principal investigator 1 Incyte Corporation $1,363.00 12/04/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240482103
Principal investigator 1 Incyte Corporation $6,232.50 12/04/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482107
Principal investigator 1 Incyte Corporation $11,232.70 12/04/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482122
Principal investigator 1 Incyte Corporation $2,000.00 12/04/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240482127
Principal investigator 1 Incyte Corporation $68.00 12/04/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240482134
Principal investigator 1 Incyte Corporation $40.00 12/04/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482141
Principal investigator 1 Incyte Corporation $8,597.10 12/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519536
Principal investigator 1 Incyte Corporation $1,595.70 12/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519540
Principal investigator 1 Incyte Corporation $11,113.10 12/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519543
Principal investigator 1 Incyte Corporation $1,270.00 12/01/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561158
Principal investigator 1 Incyte Corporation $297.00 12/01/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561162
Principal investigator 1 Incyte Corporation $635.00 12/01/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561190
Principal investigator 1 Incyte Corporation $99.00 12/01/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561347
Principal investigator 1 Incyte Corporation $138.00 12/01/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561425
Principal investigator 1 Incyte Corporation $276.00 12/01/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561459
Principal investigator 1 Incyte Corporation $83.00 12/01/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561552
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,131.57 12/01/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289091
Principal investigator 1 SANOFI PASTEUR INC. $50.00 11/27/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103545
Principal investigator 1 PFIZER INC. $24,667.64 11/26/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228817823
Principal investigator 1 Incyte Corporation $3,582.00 11/25/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519528
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $14,000.00 11/21/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1235995271
Principal investigator 1 Incyte Corporation $1,488.10 11/21/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561168
Principal investigator 1 Incyte Corporation $2,122.00 11/21/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561172
Principal investigator 1 Incyte Corporation $2,244.00 11/21/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561179
Principal investigator 1 Incyte Corporation $2,244.00 11/21/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561184
Principal investigator 1 Incyte Corporation $3,642.00 11/21/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561326
Principal investigator 1 Incyte Corporation $52.00 11/21/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561336
Principal investigator 1 Incyte Corporation $52.00 11/21/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561343
Principal investigator 1 Incyte Corporation $200.00 11/21/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561520
Principal investigator 1 Incyte Corporation $40.00 11/20/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482073
Principal investigator 1 Incyte Corporation $52.00 11/17/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561559
Principal investigator 1 Incyte Corporation $40.00 11/14/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482079
Principal investigator 1 Incyte Corporation $1,244.70 11/14/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519532
Principal investigator 1 SANOFI PASTEUR INC. $4,242.61 11/14/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103341
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,856.59 11/10/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190312821
Principal investigator 1 ABBVIE INC. $628.80 11/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202522485
Principal investigator 1 ABBVIE INC. $2,178.80 11/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202522487
Principal investigator 1 ABBVIE INC. $12,631.90 11/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522489
Principal investigator 1 ABBVIE INC. $2,125.10 11/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202520643
Principal investigator 1 ABBVIE INC. $1,745.50 11/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202520765
Principal investigator 1 ABBVIE INC. $5,493.90 11/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202520767
Principal investigator 1 PFIZER INC. $20,529.52 11/04/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228817829
Principal investigator 1 Incyte Corporation $52.00 11/03/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561372
Principal investigator 1 Incyte Corporation $99.00 11/03/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561507
Principal investigator 1 SANOFI PASTEUR INC. $10,390.47 10/31/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103550
Principal investigator 1 ABBVIE INC. $1,500.00 10/30/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202519875
Principal investigator 1 Incyte Corporation $40.00 10/29/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482038
Principal investigator 1 Incyte Corporation $40.00 10/29/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482054
Principal investigator 1 Incyte Corporation $4,785.30 10/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519524
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $912.53 10/29/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287783
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,660.00 10/27/2025 Non-covered Recipient Entity
Elite Clinical Network/ Northridge Clinical Trials
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051370
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,226.11 10/24/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287641
Principal investigator 1 SANOFI PASTEUR INC. $3,098.05 10/23/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103540
Principal investigator 1 Incyte Corporation $200.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561126
Principal investigator 1 Incyte Corporation $200.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561132
Principal investigator 1 Incyte Corporation $200.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561140
Principal investigator 1 Incyte Corporation $3,642.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561202
Principal investigator 1 Incyte Corporation $3,642.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561208
Principal investigator 1 Incyte Corporation $3,642.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561215
Principal investigator 1 Incyte Corporation $52.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561283
Principal investigator 1 Incyte Corporation $52.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561291
Principal investigator 1 Incyte Corporation $52.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561297
Principal investigator 1 Incyte Corporation $52.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561303
Principal investigator 1 Incyte Corporation $207.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561309
Principal investigator 1 Incyte Corporation $97.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561363
Principal investigator 1 Incyte Corporation $2,335.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561401
Principal investigator 1 Incyte Corporation $2,335.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561405
Principal investigator 1 Incyte Corporation $2,335.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561413
Principal investigator 1 Incyte Corporation $2,335.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561420
Principal investigator 1 Incyte Corporation $504.35 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561490
Principal investigator 1 Incyte Corporation $2,122.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561494
Principal investigator 1 Incyte Corporation $2,122.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561501
Principal investigator 1 Incyte Corporation $2,244.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561527
Principal investigator 1 Incyte Corporation $2,244.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561532
Principal investigator 1 Incyte Corporation $121.00 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561542
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,877.98 10/22/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287315
Principal investigator 1 ABBVIE INC. $5,305.17 10/16/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202517339
Principal investigator 1 SANOFI PASTEUR INC. $10,075.00 10/15/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103347
Principal investigator 1 SANOFI PASTEUR INC. $50.00 10/15/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103353
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 10/15/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103358
Principal investigator 1 SANOFI PASTEUR INC. $100.00 10/15/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103364
Principal investigator 1 SANOFI PASTEUR INC. $50.00 10/15/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103529
Principal investigator 1 SANOFI PASTEUR INC. $50.00 10/15/2025 Non-covered Recipient Entity
Northridge Clinical Trials Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103533
Principal investigator 1 ABBVIE INC. $6,486.76 10/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202516227
Principal investigator 1 ABBVIE INC. $7,632.00 10/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202516229
Principal investigator 1 ABBVIE INC. $6,354.10 10/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202516233
Principal investigator 1 ABBVIE INC. $5,280.70 10/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202516235
Principal investigator 1 ABBVIE INC. $2,125.10 10/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202516393
Principal investigator 1 ABBVIE INC. $2,033.70 10/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202516395
Principal investigator 1 Incyte Corporation $1,449.00 10/09/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482042
Principal investigator 1 Incyte Corporation $40.00 10/09/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482061
Principal investigator 1 Incyte Corporation $40.00 10/09/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482067
Principal investigator 1 Incyte Corporation $3,452.40 10/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519520
Principal investigator 1 PFIZER INC. $3,554.19 10/09/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228824411
Principal investigator 1 ABBVIE INC. $23,997.82 10/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202513355
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,282.70 10/06/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220810316
Principal investigator 1 Incyte Corporation $2,681.10 10/03/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240482050
Principal investigator 1 PFIZER INC. $664.00 10/03/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228824426
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,991.08 10/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223286341
Principal investigator 1 Incyte Corporation $1,270.00 10/02/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561113
Principal investigator 1 Incyte Corporation $198.00 10/02/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561195
Principal investigator 1 Incyte Corporation $276.00 10/02/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561379
Principal investigator 1 Incyte Corporation $83.00 10/02/2025 Non-covered Recipient Entity
NORTHRIDGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240561577
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,019.10 10/01/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286107
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $900.00 09/30/2025 Non-covered Recipient Entity
Elite Clinical Network/ Northridge Clinical Trials
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051368
Principal investigator 1 Incyte Corporation $200.00 09/25/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240481985
Principal investigator 1 Incyte Corporation $1,831.45 09/25/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240481991
Principal investigator 1 Incyte Corporation $3,642.00 09/25/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240481997
Principal investigator 1 Incyte Corporation $52.00 09/25/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240482022
Principal investigator 1 Incyte Corporation $200.00 09/25/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240482027
Principal investigator 1 Incyte Corporation $3,642.00 09/25/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240482032
Principal investigator 1 PFIZER INC. $17,808.68 09/24/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228836854
Principal investigator 1 Incyte Corporation $1,555.20 09/23/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481974
Principal investigator 1 Incyte Corporation $1,244.70 09/23/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519516
Principal investigator 1 GlaxoSmithKline, LLC. $1,400.00 09/18/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151207
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/18/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151750
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 09/18/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151762
Principal investigator 1 Incyte Corporation $80.00 09/18/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481952
Principal investigator 1 Incyte Corporation $40.00 09/18/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481963
Principal investigator 1 ABBVIE INC. $17,202.51 09/16/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202511024
Principal investigator 1 GlaxoSmithKline, LLC. $2,329.15 09/15/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192097838
Principal investigator 1 Incyte Corporation $1,567.80 09/12/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481979
Principal investigator 1 Incyte Corporation $7,231.50 09/12/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519511
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,656.00 09/12/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285349
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $724.50 09/12/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285351
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,700.00 09/08/2025 Non-covered Recipient Entity
Elite Clinical Network/ Northridge Clinical Trials
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051366
Principal investigator 1 Incyte Corporation $2,000.00 09/05/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240482002
Principal investigator 1 Incyte Corporation $10,000.00 09/05/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240482010
Principal investigator 1 Incyte Corporation $2,000.00 09/05/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240482016
Principal investigator 1 ABBVIE INC. $2,695.40 09/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202509052
Principal investigator 1 ABBVIE INC. $1,425.70 09/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509212
Principal investigator 1 Incyte Corporation $1,449.00 09/04/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481958
Principal investigator 1 Incyte Corporation $40.00 09/04/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481968
Principal investigator 1 ABBVIE INC. $4,671.00 09/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202507575
Principal investigator 1 ABBVIE INC. $7,953.50 09/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202507577
Principal investigator 1 ABBVIE INC. $7,465.20 09/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202507579
Principal investigator 1 ABBVIE INC. $9,464.60 09/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202507581
Principal investigator 1 PFIZER INC. $2,819.20 09/03/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228836736
Principal investigator 1 PFIZER INC. $8,685.72 09/03/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228836910
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,377.54 09/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284893
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 09/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284987
Principal investigator 1 GlaxoSmithKline, LLC. $60.75 08/27/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151615
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 08/27/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151627
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 08/26/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151203
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,440.96 08/21/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220810312
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,370.08 08/21/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220810314
Principal investigator 1 Incyte Corporation $2,310.30 08/21/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481941
Principal investigator 1 Incyte Corporation $3,060.00 08/21/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519498
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/19/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192097826
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/19/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192150706
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/19/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151195
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/19/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151767
Principal investigator 1 Incyte Corporation $3,319.20 08/14/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481927
Principal investigator 1 Incyte Corporation $40.00 08/14/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481934
Principal investigator 1 Incyte Corporation $2,709.00 08/14/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519507
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,771.86 08/13/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284227
Principal investigator 1 Incyte Corporation $40.00 08/07/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481946
Principal investigator 1 Incyte Corporation $6,030.00 08/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519503
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $32,310.00 08/07/2025 Non-covered Recipient Entity
Elite Clinical Network/ Northridge Clinical Trials
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051364
Principal investigator 1 ABBVIE INC. $2,683.70 08/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202503143
Principal investigator 1 ABBVIE INC. $5,389.10 08/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503145
Principal investigator 1 ABBVIE INC. $1,885.90 08/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202501812
Principal investigator 1 ABBVIE INC. $7,997.70 08/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202501904
Principal investigator 1 ABBVIE INC. $1,557.00 08/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202501906
Principal investigator 1 ABBVIE INC. $6,392.20 08/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202501908
Principal investigator 1 Eli Lilly and Company $14,000.00 08/05/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187886908
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 08/05/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192097866
Principal investigator 1 PFIZER INC. $19,443.96 08/05/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228840928
Principal investigator 1 Amgen Inc. $5,700.00 08/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246640393
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,000.00 08/01/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220810310
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,720.04 08/01/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283375
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,864.73 08/01/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283377
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $103.50 08/01/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283487
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 08/01/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283489
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 08/01/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283495
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $103.50 08/01/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283501
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 08/01/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283503
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 07/31/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151632
Principal investigator 1 Incyte Corporation $40.00 07/31/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481916
Principal investigator 1 Incyte Corporation $40.00 07/31/2025 Covered Recipient Teaching Hospital
Northridge Medical Center - Roscoe
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240481923
Principal investigator 1 Incyte Corporation $200.00 07/31/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519447
Principal investigator 1 Incyte Corporation $6,620.40 07/31/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561078
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 07/24/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192150689
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,545.60 07/23/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223282988
Principal investigator 1 Incyte Corporation $40.00 07/22/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561095
Principal investigator 1 Incyte Corporation $144.00 07/22/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 07/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217489
Principal investigator 1 GlaxoSmithKline, LLC. $108.00 07/17/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192150680
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 07/17/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192150698
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 07/17/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151775
Principal investigator 1 Incyte Corporation $2,797.20 07/17/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519444
Principal investigator 1 Incyte Corporation $40.00 07/17/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561083
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,718.82 07/16/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282738
Principal investigator 1 GlaxoSmithKline, LLC. $8,542.06 07/14/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192189478
Principal investigator 1 PFIZER INC. $2,835.90 07/11/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228841773
Principal investigator 1 Incyte Corporation $540.00 07/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519450
Principal investigator 1 Incyte Corporation $372.00 07/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519454
Principal investigator 1 Incyte Corporation $2,711.70 07/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519463
Principal investigator 1 Incyte Corporation $152.00 07/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519467
Principal investigator 1 Incyte Corporation $100.00 07/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519471
Principal investigator 1 Incyte Corporation $772.00 07/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519479
Principal investigator 1 Incyte Corporation $579.00 07/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519483
Principal investigator 1 Incyte Corporation $5,898.60 07/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519490
Principal investigator 1 Incyte Corporation $3,110.40 07/10/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561100
Principal investigator 1 Incyte Corporation $247.00 07/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519459
Principal investigator 1 Incyte Corporation $62.00 07/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519475
Principal investigator 1 Incyte Corporation $95.00 07/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519485
Principal investigator 1 Incyte Corporation $90.00 07/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519494
Principal investigator 1 Incyte Corporation $40.00 07/04/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561090
Principal investigator 1 ABBVIE INC. $8,762.60 07/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202494761
Principal investigator 1 ABBVIE INC. $3,114.00 07/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202494763
Principal investigator 1 ABBVIE INC. $5,989.20 07/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202494765
Principal investigator 1 ABBVIE INC. $2,757.40 07/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202494767
Principal investigator 1 ABBVIE INC. $6,650.90 07/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202494769
Principal investigator 1 PFIZER INC. $1,015.80 06/26/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228850302
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $941.85 06/25/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
INSPIRE LTE study No dispute reported 06/30/2026 1246431156
Principal investigator 1 Incyte Corporation $1,244.70 06/24/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519424
Principal investigator 1 Incyte Corporation $1,673.10 06/24/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561066
Principal investigator 1 GlaxoSmithKline, LLC. $2,648.10 06/23/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151185
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20,250.00 06/23/2025 Non-covered Recipient Entity
Elite Clinical Network/ Northridge Clinical Trials
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051362
Principal investigator 1 Incyte Corporation $2,840.40 06/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519400
Principal investigator 1 Incyte Corporation $100.00 06/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519407
Principal investigator 1 Incyte Corporation $200.00 06/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519412
Principal investigator 1 Incyte Corporation $351.00 06/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519415
Principal investigator 1 Incyte Corporation $62.00 06/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519429
Principal investigator 1 Incyte Corporation $100.00 06/19/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561047
Principal investigator 1 Incyte Corporation $41.00 06/19/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561059
Principal investigator 1 Incyte Corporation $240.00 06/19/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561073
Principal investigator 1 ABBVIE INC. $1,500.00 06/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202492329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209001
Principal investigator 1 Incyte Corporation $200.00 06/12/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561052
Principal investigator 1 Eli Lilly and Company $7,215.00 06/11/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187886066
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 06/06/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192150709
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58,060.12 06/06/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280942
Principal investigator 1 Incyte Corporation $100.00 06/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519403
Principal investigator 1 Incyte Corporation $900.00 06/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519419
Principal investigator 1 Incyte Corporation $1,464.30 06/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519433
Principal investigator 1 Incyte Corporation $100.00 06/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519439
Principal investigator 1 Incyte Corporation $1,449.00 06/05/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561042
Principal investigator 1 X4 Pharmaceuticals, Inc. $200.00 06/05/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension No dispute reported 06/30/2026 1253118508
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 06/04/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280628
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 06/04/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280630
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $207.00 06/04/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280644
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $207.00 06/04/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280646
Principal investigator 1 ABBVIE INC. $3,787.80 06/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489621
Principal investigator 1 ABBVIE INC. $6,361.00 06/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202489837
Principal investigator 1 ABBVIE INC. $7,953.10 06/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202489839
Principal investigator 1 ABBVIE INC. $2,893.00 06/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202489841
Principal investigator 1 GlaxoSmithKline, LLC. $243.00 06/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192097832
Principal investigator 1 GlaxoSmithKline, LLC. $108.00 06/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192097854
Principal investigator 1 GlaxoSmithKline, LLC. $400.00 06/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192097860
Principal investigator 1 GlaxoSmithKline, LLC. $121.50 06/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192150685
Principal investigator 1 GlaxoSmithKline, LLC. $400.00 06/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151623
Principal investigator 1 GlaxoSmithKline, LLC. $81.00 06/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151754
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 06/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151758
Principal investigator 1 GlaxoSmithKline, LLC. $243.00 06/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192159895
Principal investigator 1 Incyte Corporation $4,392.90 05/28/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519370
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $161.46 05/28/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280410
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $117.30 05/28/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280412
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $103.50 05/28/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280414
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 05/28/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280416
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 05/26/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151619
Principal investigator 1 Incyte Corporation $1,244.70 05/22/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519385
Principal investigator 1 Incyte Corporation $200.00 05/22/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519388
Principal investigator 1 Incyte Corporation $57.00 05/22/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519392
Principal investigator 1 Incyte Corporation $40.00 05/22/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561001
Principal investigator 1 Incyte Corporation $1,035.52 05/22/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561019
Principal investigator 1 Incyte Corporation $616.00 05/22/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561024
Principal investigator 1 Incyte Corporation $760.08 05/22/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561031
Principal investigator 1 Incyte Corporation $3,123.00 05/22/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561037
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $18,710.00 05/19/2025 Non-covered Recipient Entity
Elite Clinical Network/ Northridge Clinical Trials
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051360
Principal investigator 1 GlaxoSmithKline, LLC. $13,859.52 05/16/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151181
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,477.40 05/16/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279930
Principal investigator 1 Incyte Corporation $392.40 05/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519378
Principal investigator 1 Incyte Corporation $152.00 05/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519396
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $81.42 05/14/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279730
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 05/14/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279732
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $103.50 05/14/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279742
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,200.00 05/14/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279744
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,210.00 05/14/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279746
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,300.00 05/14/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279748
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,000.00 05/09/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
Long term extension No dispute reported 06/30/2026 1220810302
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $58.14 05/09/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
INSPIRE LTE study No dispute reported 06/30/2026 1246431162
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 05/09/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279340
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,842.18 05/09/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279368
Principal investigator 1 Incyte Corporation $3,189.60 05/08/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519382
Principal investigator 1 Incyte Corporation $1,567.80 05/08/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561007
Principal investigator 1 ABBVIE INC. $7,039.20 05/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202482727
Principal investigator 1 ABBVIE INC. $12,500.00 05/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202482729
Principal investigator 1 ABBVIE INC. $1,354.60 05/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202483059
Principal investigator 1 ABBVIE INC. $1,640.20 05/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483907
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,498.50 05/07/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220810308
Principal investigator 1 ABBVIE INC. $4,671.00 05/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202481659
Principal investigator 1 ABBVIE INC. $4,463.00 05/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202481661
Principal investigator 1 ABBVIE INC. $2,034.10 05/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202481663
Principal investigator 1 PFIZER INC. $5,671.80 05/06/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228855514
Principal investigator 1 Incyte Corporation $300.00 05/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519374
Principal investigator 1 Incyte Corporation $80.00 05/02/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561013
Principal investigator 1 GlaxoSmithKline, LLC. $9,868.84 04/28/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192189483
Principal investigator 1 Incyte Corporation $3,956.40 04/28/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519350
Principal investigator 1 Incyte Corporation $41.00 04/28/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560969
Principal investigator 1 Incyte Corporation $280.00 04/28/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560988
Principal investigator 1 Incyte Corporation $400.00 04/28/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560995
Principal investigator 1 ABBVIE INC. $7,900.82 04/24/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202479266
Principal investigator 1 Incyte Corporation $1,464.30 04/23/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519353
Principal investigator 1 Incyte Corporation $8,208.00 04/23/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560993
Principal investigator 1 Incyte Corporation $15,465.00 04/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519365
Principal investigator 1 Incyte Corporation $4,473.00 04/15/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560975
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $36,403.08 04/11/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278038
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,498.50 04/09/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220810306
Principal investigator 1 GlaxoSmithKline, LLC. $40.50 04/09/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192097843
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 04/09/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151199
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 04/09/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151780
Principal investigator 1 Incyte Corporation $15.00 04/08/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519357
Principal investigator 1 Incyte Corporation $392.40 04/08/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519361
Principal investigator 1 Incyte Corporation $2,917.80 04/08/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560981
Principal investigator 1 PFIZER INC. $2,299.08 04/08/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228857045
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $322.92 04/04/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277584
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 04/04/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277586
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,347.00 04/04/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277588
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 04/04/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277618
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 04/04/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277620
Principal investigator 1 X4 Pharmaceuticals, Inc. $78.00 04/04/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension No dispute reported 06/30/2026 1253118486
Principal investigator 1 X4 Pharmaceuticals, Inc. $84.50 04/04/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension No dispute reported 06/30/2026 1253118492
Principal investigator 1 X4 Pharmaceuticals, Inc. $84.50 04/04/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension No dispute reported 06/30/2026 1253118497
Principal investigator 1 X4 Pharmaceuticals, Inc. $84.50 04/04/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension No dispute reported 06/30/2026 1253118501
Principal investigator 1 X4 Pharmaceuticals, Inc. $84.50 04/04/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension No dispute reported 06/30/2026 1253118505
Principal investigator 1 X4 Pharmaceuticals, Inc. $2,121.60 04/04/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension No dispute reported 06/30/2026 1253118517
Principal investigator 1 ABBVIE INC. $1,640.20 04/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202472456
Principal investigator 1 ABBVIE INC. $1,557.00 04/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202472578
Principal investigator 1 ABBVIE INC. $1,410.10 04/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202472582
Principal investigator 1 ABBVIE INC. $1,615.90 04/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202472961
Principal investigator 1 ABBVIE INC. $6,432.50 04/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202472965
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $941.85 04/02/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
INSPIRE LTE study No dispute reported 06/30/2026 1246431158
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 04/02/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277484
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $900.00 04/02/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277500
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 04/02/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277502
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 04/01/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277308
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 04/01/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277310
Principal investigator 1 GlaxoSmithKline, LLC. $8,000.00 03/27/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192150694
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 03/27/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192151190
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,100.00 03/26/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277051
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 03/26/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277053
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 03/25/2025 Non-covered Recipient Entity
California Dermatology Institute-Thousand Oaks
Speso moderate to severe HS Phase IIb/III No dispute reported 06/30/2026 1220771229
Principal investigator 1 Incyte Corporation $3,582.00 03/25/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560947
Principal investigator 1 PFIZER INC. $2,485.38 03/22/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228858706
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 03/21/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192097848
Principal investigator 1 GlaxoSmithKline, LLC. $108.00 03/21/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192150702
Principal investigator 1 GlaxoSmithKline, LLC. $15,898.29 03/21/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192150713
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 03/21/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151211
Principal investigator 1 GlaxoSmithKline, LLC. $162.00 03/21/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151637
Principal investigator 1 GlaxoSmithKline, LLC. $81.00 03/21/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151770
Principal investigator 1 UCB SA $19,653.35 03/21/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB COMPARED TO USTEKINUMAB IN CHILDREN AND ADOLESCENTS FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1246659122
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,100.00 03/20/2025 Non-covered Recipient Entity
Elite Clinical Network/ Northridge Clinical Trials
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051358
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,595.00 03/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184174266
Principal investigator 1 Incyte Corporation $93.84 03/14/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560912
Principal investigator 1 Incyte Corporation $198.00 03/14/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560916
Principal investigator 1 Incyte Corporation $117.30 03/14/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560922
Principal investigator 1 Incyte Corporation $50.00 03/14/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560931
Principal investigator 1 Incyte Corporation $91.08 03/14/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560953
Principal investigator 1 Incyte Corporation $123.00 03/14/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560958
Principal investigator 1 Incyte Corporation $545.08 03/14/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.50 03/14/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184173892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $380.00 03/14/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184173894
Principal investigator 1 ABBVIE INC. $6,005.80 03/12/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462676
Principal investigator 1 Incyte Corporation $3,511.80 03/11/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240560937
Principal investigator 1 ABBVIE INC. $3,065.90 03/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460313
Principal investigator 1 ABBVIE INC. $1,254.10 03/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202460317
Principal investigator 1 ABBVIE INC. $5,954.10 03/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202460445
Principal investigator 1 ABBVIE INC. $3,189.80 03/07/2025 Non-covered Recipient Entity
CALIFORNIA DERMATOLOGY INSTITUTE
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202461719
Principal investigator 1 ABBVIE INC. $9,148.70 03/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202461823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,187.84 03/07/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276131
Principal investigator 1 ABBVIE INC. $12,304.30 03/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202458405
Principal investigator 1 ABBVIE INC. $6,233.20 03/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202455598
Principal investigator 1 UCB SA $40,746.60 02/27/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658338
Principal investigator 1 PFIZER INC. $9,023.82 02/26/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228836863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $77,540.55 02/26/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275651
Principal investigator 1 ABBVIE INC. $19,737.04 02/25/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202453803
Principal investigator 1 Incyte Corporation $6,726.60 02/25/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 02/20/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155066
Principal investigator 1 X4 Pharmaceuticals, Inc. $1,909.44 02/20/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension No dispute reported 06/30/2026 1253118513
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $37,805.52 02/19/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275387
Principal investigator 1 ABBVIE INC. $9,984.20 02/11/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202450508
Principal investigator 1 Incyte Corporation $392.40 02/11/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519575
Principal investigator 1 Incyte Corporation $41.00 02/11/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561605
Principal investigator 1 Incyte Corporation $3,346.20 02/11/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561612
Principal investigator 1 Incyte Corporation $320.00 02/11/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561620
Principal investigator 1 GlaxoSmithKline, LLC. $9,841.52 02/10/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192151611
Principal investigator 1 ABBVIE INC. $9,775.70 02/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202448113
Principal investigator 1 ABBVIE INC. $7,561.80 02/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202448117
Principal investigator 1 ABBVIE INC. $1,429.60 02/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202448156
Principal investigator 1 ABBVIE INC. $6,462.00 02/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202448159
Principal investigator 1 ABBVIE INC. $8,856.60 02/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202444823
Principal investigator 1 Incyte Corporation $4,173.30 02/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519571
Principal investigator 1 PFIZER INC. $8,179.53 02/05/2025 Non-covered Recipient Entity
Northridge Clinical Trials
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228836857
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $755.00 02/05/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274865
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 02/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274689
Principal investigator 1 UCB SA $14,913.00 01/31/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1246657000
Principal investigator 1 Amgen Inc. $2,431.00 01/30/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) No dispute reported 06/30/2026 1246645461
Principal investigator 1 Incyte Corporation $1,595.70 01/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519559
Principal investigator 1 Incyte Corporation $8,000.00 01/29/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561583
Principal investigator 1 Incyte Corporation $4,665.60 01/29/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561587
Principal investigator 1 Eli Lilly and Company $83,439.00 01/28/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187887328
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 01/27/2025 Non-covered Recipient Entity
California Dermatology Institute-Thousand Oaks
Speso moderate to severe HS Phase IIb/III No dispute reported 06/30/2026 1220771227
Principal investigator 1 Eli Lilly and Company $3,277.86 01/27/2025 Non-covered Recipient Entity
MEHRDAD KEVIN ARIANI MD
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187886924
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,817.24 01/27/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
INSPIRE LTE study No dispute reported 06/30/2026 1246431160
Principal investigator 1 Avita Medical Americas, LLC $11,935.00 01/23/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
CTP010 Additional Vitiligo Study No dispute reported 06/30/2026 1171903449
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $310.50 01/22/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274373
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 01/22/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274375
Principal investigator 1 Incyte Corporation $2,970.00 01/21/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 01/20/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184148956
Principal investigator 1 Incyte Corporation $3,362.40 01/17/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519567
Principal investigator 1 GlaxoSmithKline, LLC. $13,338.28 01/09/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192159899
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,046.80 01/07/2025 Non-covered Recipient Entity
Clinical Trials Research Institute
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220810304
Principal investigator 1 Incyte Corporation $392.40 01/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240519555
Principal investigator 1 Incyte Corporation $1,908.90 01/07/2025 Non-covered Recipient Entity
NORTHRIDGE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240561594
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,389.15 01/03/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273549
Principal investigator 1 Amgen Inc. $92,480.45 01/02/2025 Non-covered Recipient Entity
CALIFORNIA DERMATOLOGY INSTITUTE
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246639849
Principal investigator 1 Amgen Inc. $86,611.36 01/02/2025 Non-covered Recipient Entity
NORTHRIDGE CLINICAL TRIALS
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246645470